chevron_leftBack
As of 13 June 2026, 180 Life Sciences Corp. has a market cap of $1.08B USD, ranking #10260 globally and #2111 in the United States.
It ranks #902 in the Healthcare sector, and #167 in the Biotechnology industry.
Key Stats
Market Cap
$1.08BUSD
Enterprise Value
$1.08BUSD
EBITDA (TTM)
-$6.45MUSD
Net Income (TTM)
-$17.22MUSD
PB Ratio
7.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Lloyd Jordan
open_in_new
Employees
4
Founded
2016
Website
180lifesciences.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -7.5% | 135% | 682% | 534% | 429% | 281% |
News
Loading...
ETHZ Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ETHZ
(ATNF)
180 Life Sciences Corp Ordinary Shares
ISIN: US68236V3024
Shares Out.:
Shares Outstanding:
154.032M1
Shares Float:
151.368M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.04 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About 180 Life Sciences Corp.
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain. 180 Life Sciences Corp. is headquartered in Palo Alto, California.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
17K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
15K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
2K%
|
-
|
|
NYSE: IQV
|
$26.3B
2K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
2K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
2K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
4K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
4K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
4K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
4K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
2K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
2K%
|
-
|
chevron_leftBack